Absent T Lymphocytes

Search Trials
Long-term Follow-up of Subjects Treated With CARv3-TEAM-E T Cells
Status:
Not yet recruiting
Last Changed:
Aug 27, 2021
First Changed:
Aug 27, 2021
Disease(s):
Glioblastoma Recurrent, EGFR vIII Mutant
Intervention(s):
Disease assessmentsTumor BiopsyBlood test
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
Status:
Completed
Last Changed:
Sep 18, 2018
First Changed:
Apr 11, 2017
Disease(s):
Positron-Emission Tomography
Intervention(s):
⁸⁹Zr-Df-IAB22M2C Infusion
Rare Disease Patient Registry & Natural History Study – Coordination of Rare Diseases at Sanford
Status:
Recruiting
Last Changed:
Dec 10, 2020
First Changed:
Feb 15, 2013
Disease(s):
Rare Disorders
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy
Status:
Completed
Last Changed:
Nov 8, 2019
First Changed:
Dec 18, 2009
Disease(s):
Anaplastic Large Cell Lymphoma, ALK-Negative
Intervention(s):
Autologous Hematopoietic Stem Cell TransplantationCarmustineCytarabineEtoposideLenalidomideMelphalanRituximab
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Status:
Recruiting
Last Changed:
May 5, 2021
First Changed:
Feb 21, 2019
Disease(s):
Melanoma
Intervention(s):
XmAb®22841Pembrolizumab (Keytruda®)

Connect. Empower. Inspire.